# Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma

> **NCT01552967** · PHASE2 · UNKNOWN · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01552967
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2013-08
- **Final completion:** 2014-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01552967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01552967, "Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01552967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*